CD33 and acute myeloid leukemia: As a myeloid differentiation antigen, CD33 is expressed on the leukemic blasts of the majority of patients with AML [13, 14], which has led to a long-standing interest in developing immunotherapies directed against CD33 for the treatment of AML.